BioWorld Asia

March 18, 2009

View Archived Issues

Kenta Biotech Gets CHF12M for Anti-infective Antibodies

Kenta Biotech AG raised CHF12 million (US$10.1 million) in an internal Series B round that will fund the entry into the clinic of its second therapeutic antibody. (BioWorld International) Read More

Cytos Shares Plunge on Hypertension Vaccine Miss

Read More

Scientists are Near Harnessing Power of Nanoparticles in Cancer

Read More

GW Pharma Hits the Mark in Phase III Sativex MS Trial

Read More

Stabilitech Bucks the Trend, Raises £3.3M for Technology

Read More

Europe's Biotech Firms Said to 'Face Catastrophe'

Read More

Shareholder Pressure Nixes Progen's Merger with Avexa

Read More

Roche, Genentech Finally Agree to Acquisition at $95 per Share

Read More

Other News To Note

Read More